Natarajan Sethuraman Sells 2,642 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 2,642 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.09, for a total value of $39,867.78. Following the completion of the transaction, the insider now directly owns 183,816 shares in the company, valued at approximately $2,773,783.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Natarajan Sethuraman also recently made the following trade(s):

• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.24, for a total transaction of $9,144.00.
• On Monday, July 15th, Natarajan Sethuraman sold 638 shares of Entrada Therapeutics stock. The shares were sold at an average price of $18.00, for a total transaction of $11,484.00.
• On Friday, July 12th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $10,800.00.

Entrada Therapeutics Trading Down 2.1 %

Entrada Therapeutics stock opened at $14.72 on Wednesday. Entrada Therapeutics, Inc. has a 1 year low of $10.75 and a 1 year high of $18.17. The company’s 50-day moving average is $16.03 and its two-hundred day moving average is $14.65. The company has a market cap of $496.93 million, a PE ratio of 23.37 and a beta of -0.24.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a net margin of 43.63% and a return on equity of 35.16%. The firm had revenue of $94.69 million for the quarter, compared to analysts’ expectations of $55.00 million. Research analysts forecast that Entrada Therapeutics, Inc. will post 0.68 EPS for the current year.

Institutional Trading of Entrada Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company lifted its holdings in Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock worth $814,000 after acquiring an additional 2,146 shares in the last quarter. Marshall Wace LLP increased its stake in Entrada Therapeutics by 27.5% during the 2nd quarter. Marshall Wace LLP now owns 65,943 shares of the company’s stock worth $940,000 after purchasing an additional 14,220 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Entrada Therapeutics during the 2nd quarter worth approximately $636,000. American Century Companies Inc. lifted its stake in Entrada Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock valued at $5,486,000 after buying an additional 18,625 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of Entrada Therapeutics by 135.1% in the second quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock valued at $190,000 after buying an additional 7,682 shares during the period. 86.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TRDA. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Entrada Therapeutics in a report on Wednesday, August 14th. Oppenheimer reissued an “outperform” rating and issued a $25.00 target price on shares of Entrada Therapeutics in a research note on Monday, August 26th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.